Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.41 |
| ▸ | ITGAV | P06756 | 4/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12463784 | 1.00 | NNMT (0.47) | NNMTFFAR1CHRNA7CTSAKMT2A | |
| SCHEMBL4475092 | 1.00 | NNMT (0.47) | NNMTFFAR1CHRNA7CTSAKMT2A | |
| SCHEMBL7081677 | 0.87 | NNMT (0.46) | NNMTCHRNA7KMT2AALDH1A1POLB | |
| SCHEMBL5091415 | 0.87 | NNMT (0.46) | NNMTCHRNA7KMT2AALDH1A1POLB | |
| SCHEMBL16245308 | 0.86 | MEN1 (0.44) | NNMTFFAR1CHRNA7CTSAKMT2A | |
| SCHEMBL19144265 | 0.85 | NNMT (0.41) | NNMTFFAR1CHRNA7CTSAKMT2A | |
| SCHEMBL19143486 | 0.85 | NNMT (0.41) | NNMTFFAR1CHRNA7CTSAKMT2A | |
| SCHEMBL6221566 | 0.84 | ITGB3 (0.50) | NNMTFFAR1CHRNA7CTSAKMT2A | |
| SCHEMBL6106081 | 0.83 | NNMT (0.43) | NNMTFFAR1CHRNA7KMT2AALDH1A1 | |
| SCHEMBL20153392 | 0.83 | NNMT (0.43) | NNMTFFAR1CHRNA7KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1230240-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF IMIDAZOLIDINONE ALPHA V INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-07-23 | — | — | EP | claimed |
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-110167934-B | Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-110167935-B | 3-substituted propionic acids as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3707142-B1 | PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190134156-A1 | TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| EP-3305900-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | Nuevolution A/S (DK) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017189988-A1 | TISSUE PROTECTIVE PEPTIDES FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | ARAIM PHARMACEUTICALS, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20130245283-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20070232660-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | ALLERGAN, INC. | 2007-10-04 | — | — | US | disclosed |
| US-6646130-B2 | Comprises mixtures of alky esters of 3-(6-methoxy-pyridin-3-yl); for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastasis | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030045555-A1 | Process to chiral integrin antagonist beta-amino acid intermediate | MERCK SHARP & DOHME CORP. | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232660-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | NNMT 2648/4885FFAR1 100/4885CHRNA7 839/4885 |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | NNMT 1640/4885FFAR1 1389/4885CHRNA7 1807/4885 |
| US-11884661-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | NNMT 3147/4885FFAR1 272/4885CHRNA7 498/4885 |
| US-20130245283-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | NNMT 2648/4885FFAR1 100/4885CHRNA7 839/4885 |
| US-20030045555-A1 | Process to chiral integrin antagonist beta-amino acid intermediate | ITGB1, ITGB3, ITGA1 | NNMT 2517/4885FFAR1 145/4885CHRNA7 122/4885 |
| US-11292802-B2 | Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors | ITGB1, ITGAV, ITGA1 | NNMT 3187/4885FFAR1 871/4885CHRNA7 1335/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | NNMT 3317/4885FFAR1 1171/4885CHRNA7 673/4885 |
| US-20100280250-A1 | THERAPEUTIC AND DELIVERY METHODS OF PROSTAGLANDIN EP4 AGONISTS | PTGER4, PTGER1, PTGER3 | NNMT 2648/4885FFAR1 100/4885CHRNA7 839/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | NNMT 3145/4885FFAR1 1343/4885CHRNA7 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.